Abstract 41P
Background
Triple-negative breast cancer (TNBC) is associated with more aggressive disease and worse survival compared to other breast cancer subtypes. We aim to analyze the role of oncogenic mir-223 as a possible negative driving factor in TNBC through its prognostic value and association with unfavorable clinicopathologic characteristic.
Methods
We retrospectively analyzed the association of pre-treatment mir-223 expression with clinicopathologic characteristics and 3-years overall survival (OS) of Indonesian TNBC patients treated in a tertiary center during 2014-2017. Cytokeratin5/6 (CK5/6) and Epidermal Growth Factor Receptor (EGFR) expressions were examined using immunohistochemistry by 2 independent blinded pathologists. Mir-223 level of tumor tissue was measured using Real-Time qRT-PCR. Cutoff value for mir-223 was determined using Receiver Operating Curve (ROC). Chi-square and Fisher’s exact tests were used to analyze the association between categorical variables, while Kaplan-Meier curve was used to perform survival analysis.
Results
Fifty-three stage I-IV TNBC patients were included in the analysis. The mean age of our patients was 51.3 years old. Early stage, locally advanced stage, and metastatic disease respectively were found in 7 (13.2%), 38 (71.7%), and 8 (15.1%) patients. The optimal cutoff value for mir-223 was 23.435 (AUC: 0.706, 95%CI: 0.565-0.848; p: 0.01; Sensitivity: 78.6%; Specificity: 56%) and was used to classify mir-223 expression into over- and under-expressed groups. Mir-223 overexpression was associated with increased expression of EGFR (69.7% vs. 35%, p: 0.022) and lower 3-years OS (33.3% vs. 70%; mean OS±SE (months): 25.66±1.58 vs. 30.23±1.99; p log rank: 0.029). No significant association was observed between mir-223 expression with other clinicopathologic characteristics (age, BMI, stage, tumor size, nodal status, distant metastasis, and CK5/6 expression).
Conclusions
Pre-treatment mir-223 level of expression in Indonesian TNBC patients is correlated with poor survival through increase of EGFR expression. Thus, targeting mir-223 becomes a potential therapeutic strategy for TNBC patients. However, further study is needed to validate this result.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
95P - Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer
Presenter: Tatsuki Ikoma
Session: e-Poster Display Session
96P - Early-onset colorectal cancer prognosis, conflict resolution, review of literature and meta-analysis
Presenter: Ereny Poles
Session: e-Poster Display Session
97P - A population-based study to assess the associations of rural residence and low socioeconomic status (SES) with cardiovascular disease (CVD) in patients with colorectal cancer (CRC)
Presenter: Atul Batra
Session: e-Poster Display Session
98P - Operational challenges of an Asian Pacific (APAC) academic oncology clinical trial
Presenter: Daphne Day
Session: e-Poster Display Session
99P - Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions
Presenter: Veronica Diermayr
Session: e-Poster Display Session
100P - Individualized treatment of advanced digestive system tumour guided by PDTX mouse model: A multicenter trial
Presenter: yuan cheng
Session: e-Poster Display Session
101P - HIF1-α depletion overcomes resistance to oxaliplatin in colorectal cancer via ERK signalling pathway
Presenter: Se Jun Park
Session: e-Poster Display Session
102P - Colorectal cancer organoids culture exploits new neoadjuvant therapy resistance mechanisms and therapeutic targets
Presenter: Yun Deng
Session: e-Poster Display Session
103P - Comprehensive genomic landscape in younger and older Chinese patients with colorectal cancer
Presenter: Huina Wang
Session: e-Poster Display Session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session